Validation of an UHPLC–MS/MS Assay for the Quantification of Isoniazid and Four Major Metabolites in Human Plasma
Biomedical Chromatography · 2026-09 · 40 (9)
DOI: 10.1002/bmc.70550 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 17.07.2026. Verfasst von David Nerguizian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, …. Hauptthemen laut MEDLINE: Isoniazid, Tandem Mass Spectrometry, Liquid Chromatography-Mass Spectrometry, Antitubercular Agents. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases (NIAID), NICHD NIH HHS.
Abstract (Originalsprache)
Isoniazid (INH) is a key component of tuberculosis treatment regimens but is also associated with hepatotoxicity. This toxicity is mediated in part by its metabolites, but some degrade rapidly in plasma. A rapid freeze/thaw process with a methanol protein precipitation extraction was developed to slow the rapid degradation of acetylisoniazid (AcINH) into isonicotinic acid (INA) and acetylhydrazine (AcHZ) in human plasma. An assay consisting of two UHPLC–MS/MS methods was developed and validated to determine concentrations of INH and four of its metabolites in human plasma: the “polar” method covering AcINH and INA, and the “nonpolar” method covering p‐tolualdehyde derivatized AcHZ, hydrazine (HZ), and INH. Polar and nonpolar method chromatographic separation was accomplished with biphenyl or C18 columns, respectively, mobile phases of 4 mM ammonium formate in water or acetonitrile, and method specific gradient conditions. The validated range for AcINH, INA, and INH was 10.0 to 5000 ng/mL and for AcHZ and HZ was 10.0 to 500 ng/mL from 0.1 mL of plasma, respectively. Though other groups have validated methods to quantitate some or all of these analytes, none have adequately characterized or addressed AcINH degradation. This validated assay will help facilitate a better understanding of INH metabolite disposition and relationships with toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
ORCID-Profile: David Nerguizian, Kristina M Brooks
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases (NIAID)
- NICHD NIH HHS
- National Institutes of Health (NIH)
- National Institute of Mental Health (NIMH)
Zitieren
APA
Nerguizian, D., Klein, B., Abdelmawla, F., Gomez, J., Anderson, P. L., Bushman, L., & Brooks, K. M. (2026). Validation of an UHPLC–MS/MS Assay for the Quantification of Isoniazid and Four Major Metabolites in Human Plasma. Biomedical Chromatography, 40(9). https://doi.org/10.1002/bmc.70550
Vancouver
Nerguizian D, Klein B, Abdelmawla F, Gomez J, Anderson PL, Bushman L, et al. Validation of an UHPLC–MS/MS Assay for the Quantification of Isoniazid and Four Major Metabolites in Human Plasma. Biomedical Chromatography. 2026;40(9). doi:10.1002/bmc.70550
BibTeX
@article{Nerguizian2026,
author = {Nerguizian, David and Klein, Brandon and Abdelmawla, Farah and Gomez, Joe and Anderson, Peter L and Bushman, Lane and Brooks, Kristina M},
title = {Validation of an UHPLC–MS/MS Assay for the Quantification of Isoniazid and Four Major Metabolites in Human Plasma},
journal = {Biomedical Chromatography},
year = {2026},
volume = {40},
number = {9},
doi = {10.1002/bmc.70550}
}
EUVIMED